Benchmark Reiterates “Buy” Rating for Biofrontera (NASDAQ:BFRI)

Benchmark reissued their buy rating on shares of Biofrontera (NASDAQ:BFRI) in a report published on Friday morning,Benzinga reports. The firm currently has a $7.00 price target on the stock.

Biofrontera Trading Down 8.4 %

BFRI opened at $0.67 on Friday. The firm’s fifty day simple moving average is $1.02 and its 200 day simple moving average is $1.08. The stock has a market capitalization of $3.72 million, a P/E ratio of -0.30 and a beta of 0.50. Biofrontera has a 12 month low of $0.61 and a 12 month high of $4.04.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.